JPRN-UMIN000007696已完成未知
A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer. - SOAC-1101
Chiba surgical oncology development association0 个研究点目标入组 200 人开始时间: 2012年4月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Serious diarrea 2) Serious postoperative complications 3) Serious drug hypersensitivity 4) Pregnant or nursing 5) Serious coexisting illness 1; diabetes mellitus, uncontrolled or controlled with insulin 2; uncontrolled hypertension 3; liver cirrhosis 4; renal disfaunction 5; severe pulmonary dysfunction 6; active infection 7; history of myocardial infarction, unstable angina within 6 months prior to the registration 6) Active synchronous or metachronous malignancy other than carcinoma in situ 7) Sensory neuropathy 8) Severe mental disorders 9) Not suitable for participating in the study for any other reason
研究者
相似试验
招募中
2 期
Randomized phase II study with UFT capsule /LV or UFT E-granule /LV adjuvant chemotherapy for patients with completely resected high-risk stage II and III colorectal cancercolorecrtal cancerJPRN-UMIN000010980HORE120
招募中
2 期
A phaseII randomized trial of UFT for the patients completely resected pathological Breast cancerBreast cancerJPRN-UMIN000004586Ryukyu Breast Club140
进行中（未招募）
不适用
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-CZPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176
进行中（未招募）
不适用
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-BEPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176
进行中（未招募）
1 期
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-FRPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176